Skip to main content

2015 | OriginalPaper | Buchkapitel

33. Autoimmunerkrankungen

verfasst von : Brigitte Storch-Hagenlocher, Dr., Brigitte Wildemann, Prof. Dr., Peter Berlit, Prof. Dr., Markus Krämer, PD Dr.

Erschienen in: NeuroIntensiv

Verlag: Springer Berlin Heidelberg

Zusammenfassung

In diesem Kapitel werden die typischen autoimmunologischen Erkrankungen wie fulminante entzündliche demyelinisierende Erkrankungen, Autoimmunenzephalitiden, Vaskulitiden, SLE und Sarkoidose zusammengefasst. Erkrankungen wie die ADEM sind verbunden mit rasch progredienten neurologischen Defiziten bis zur Bewusstseinsstörung mit Zeichen erhöhter ICP, Anfällen und Einbruch der vitalen Funktionen wie Atmung und Kreislauf, wodurch eine Intensivbehandlung notwendig wird. Autoimmune Enzephalopathien sind Erkrankungen der grauen Substanz, die durch den Nachweis distinkter Autoantikörper in Serum und/oder Liquor diagnostiziert werden können, ob nun paraneoplastischer Ätiologie oder idiopathisch bedingt. Die zerebrale Vaskulitis, isoliert wie begleitend zu umschriebenen systemischen Vaskulitiden, präsentiert sich oft unter dem Bild eines Schlaganfalls mit oder ohne Kopfschmerzen, psychopathologischen Auffälligkeiten oder epileptischen Anfällen. Auch die Sarkoidose gehört zu diesen Krankheiten, wobei die Neurosarkoidose eher subakut verläuft. Eine neurologische Beteiligung bei SLE verläuft typischerweise chronisch progredient mit Schüben. Die Differenzialdiagnose ist oft schwierig, wobei die Therapie in allen Fällen eine Immunsuppression einschließt (Coriticoidstoß, PE, IVIGs, Cyclophosphamid u. a.).
Literatur
1.
Zurück zum Zitat Apak RA, Anlar B, Saatci I (1999) A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 21:279–282PubMedCrossRef Apak RA, Anlar B, Saatci I (1999) A case of relapsing acute disseminated encephalomyelitis with high dose corticosteroid treatment. Brain Dev 21:279–282PubMedCrossRef
2.
Zurück zum Zitat Bizzi A, Ulug AM, Crawford TO, Passe T, Bugiani M, Bryan RN, Barker PB (2001) Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 22:1125–1130PubMed Bizzi A, Ulug AM, Crawford TO, Passe T, Bugiani M, Bryan RN, Barker PB (2001) Quantitative proton MR spectroscopic imaging in acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 22:1125–1130PubMed
3.
Zurück zum Zitat Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG (2000) Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123(12):2407–2422PubMedCrossRef Dale RC, de Sousa C, Chong WK, Cox TC, Harding B, Neville BG (2000) Acute disseminated encephalomyelitis, multiphasic disseminated encephalomyelitis and multiple sclerosis in children. Brain 123(12):2407–2422PubMedCrossRef
4.
Zurück zum Zitat Finsterer J, Grass R, Stollberger C, Mamoli B (1998) Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol 21:258–261PubMed Finsterer J, Grass R, Stollberger C, Mamoli B (1998) Immunoglobulins in acute, parainfectious, disseminated encephalo-myelitis. Clin Neuropharmacol 21:258–261PubMed
5.
Zurück zum Zitat Gupte G, Stonehouse M, Wassmer E, Coad NA, Whitehouse WP (2003) Acute disseminated encephalomyelitis: a review of 18 cases in childhood. J Paediatr Child Health 39:336–342PubMedCrossRef Gupte G, Stonehouse M, Wassmer E, Coad NA, Whitehouse WP (2003) Acute disseminated encephalomyelitis: a review of 18 cases in childhood. J Paediatr Child Health 39:336–342PubMedCrossRef
6.
Zurück zum Zitat Haase CG, Faustmann PM, Diener H (1999) Idiopathic inflammatory demyelinating diseases of the central nervous system: differentiating between acute disseminated encephalomyelitis and malignant multiple sclerosis. J Clin Neurosci 6:221–226PubMedCrossRef Haase CG, Faustmann PM, Diener H (1999) Idiopathic inflammatory demyelinating diseases of the central nervous system: differentiating between acute disseminated encephalomyelitis and malignant multiple sclerosis. J Clin Neurosci 6:221–226PubMedCrossRef
7.
Zurück zum Zitat Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR (2003) Neurocognitive outcome after acute disseminated encephalomyelitis. Pediatr Neurol 29:117–123PubMedCrossRef Hahn CD, Miles BS, MacGregor DL, Blaser SI, Banwell BL, Hetherington CR (2003) Neurocognitive outcome after acute disseminated encephalomyelitis. Pediatr Neurol 29:117–123PubMedCrossRef
8.
Zurück zum Zitat Hart MN, Earle K (1975) Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 38:585–591PubMedPubMedCentralCrossRef Hart MN, Earle K (1975) Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 38:585–591PubMedPubMedCentralCrossRef
9.
Zurück zum Zitat Hurst EW (1941) Acute haemorrhagic leuco-encephalitis, a previuosly undefined entity. Medical Journal of Australia 2:1–6 Hurst EW (1941) Acute haemorrhagic leuco-encephalitis, a previuosly undefined entity. Medical Journal of Australia 2:1–6
10.
Zurück zum Zitat Inglese M, Salvi F, Iannucci G, Mancardi GL, Mascalchi M, Filippi M (2002) Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 23:267–272PubMed Inglese M, Salvi F, Iannucci G, Mancardi GL, Mascalchi M, Filippi M (2002) Magnetization transfer and diffusion tensor MR imaging of acute disseminated encephalomyelitis. AJNR Am J Neuroradiol 23:267–272PubMed
11.
Zurück zum Zitat Ichiyama T, Shoji H, Kato M (2002) Cerebrospinal fluid levels of cytokines and soluble tumour necrosis factor receptor in acute disseminated encephalomyelitis. Eur J Pediatr 161:133–137PubMedCrossRef Ichiyama T, Shoji H, Kato M (2002) Cerebrospinal fluid levels of cytokines and soluble tumour necrosis factor receptor in acute disseminated encephalomyelitis. Eur J Pediatr 161:133–137PubMedCrossRef
12.
Zurück zum Zitat Krupp LB, Banwell B, Tenembaum S (2007) Consensus definitions proposed for pediatric multiple sclerosis and related childhood disorders. Neurology 68(Suppl 2):7–12 (for the International Pediatric MS Study Group)CrossRef Krupp LB, Banwell B, Tenembaum S (2007) Consensus definitions proposed for pediatric multiple sclerosis and related childhood disorders. Neurology 68(Suppl 2):7–12 (for the International Pediatric MS Study Group)CrossRef
13.
Zurück zum Zitat Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH Jr. (1995) Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 45:824–827PubMedCrossRef Kanter DS, Horensky D, Sperling RA, Kaplan JD, Malachowski ME, Churchill WH Jr. (1995) Plasmapheresis in fulminant acute disseminated encephalomyelitis. Neurology 45:824–827PubMedCrossRef
14.
Zurück zum Zitat Markus R, Brew BJ, Turner J, Pell M (1997) Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry 63:551PubMedPubMedCentralCrossRef Markus R, Brew BJ, Turner J, Pell M (1997) Successful outcome with aggressive treatment of acute haemorrhagic leukoencephalitis. J Neurol Neurosurg Psychiatry 63:551PubMedPubMedCentralCrossRef
15.
Zurück zum Zitat Niedermayer I, Deinzer M, Moringlane JR, Feiden W (2000) Neuropathological and neuroradiological aspects of acute disseminated encephalomyelitis (ADEM). Radiologe 40:1030–1035PubMedCrossRef Niedermayer I, Deinzer M, Moringlane JR, Feiden W (2000) Neuropathological and neuroradiological aspects of acute disseminated encephalomyelitis (ADEM). Radiologe 40:1030–1035PubMedCrossRef
16.
Zurück zum Zitat Pasternak JF, De Vivo DC, Prensky AL (1980) Steroid-responsive encephalomyelitis in childhood. Neurology 30:481–486PubMedCrossRef Pasternak JF, De Vivo DC, Prensky AL (1980) Steroid-responsive encephalomyelitis in childhood. Neurology 30:481–486PubMedCrossRef
17.
Zurück zum Zitat Pfausler B, Engelhardt K, Kampfl A, Spiss H, Taferner E, Schmutzhard E (2002) Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. Eur J Neurol 9:93–96PubMedCrossRef Pfausler B, Engelhardt K, Kampfl A, Spiss H, Taferner E, Schmutzhard E (2002) Post-infectious central and peripheral nervous system diseases complicating Mycoplasma pneumoniae infection. Report of three cases and review of the literature. Eur J Neurol 9:93–96PubMedCrossRef
18.
Zurück zum Zitat Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K (1992) Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86:579–585PubMedCrossRef Poser S, Luer W, Bruhn H, Frahm J, Bruck Y, Felgenhauer K (1992) Acute demyelinating disease. Classification and non-invasive diagnosis. Acta Neurol Scand 86:579–585PubMedCrossRef
19.
Zurück zum Zitat Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, Varettoni M, Zappasodi P, Moglia A, Lazzarino M, Costa A (2007) Severe steroid-resistant postinfectious encephalomyelitis: general features and effects of IVIg. J Neurol 254:1518–1523PubMedCrossRef Ravaglia S, Corso A, Piccolo G, Lozza A, Alfonsi E, Mangiacavalli S, Varettoni M, Zappasodi P, Moglia A, Lazzarino M, Costa A (2007) Severe steroid-resistant postinfectious encephalomyelitis: general features and effects of IVIg. J Neurol 254:1518–1523PubMedCrossRef
20.
Zurück zum Zitat Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B (2001) Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56:1313–1318PubMedCrossRef Schwarz S, Mohr A, Knauth M, Wildemann B, Storch-Hagenlocher B (2001) Acute disseminated encephalomyelitis: a follow-up study of 40 adult patients. Neurology 56:1313–1318PubMedCrossRef
21.
Zurück zum Zitat Schwarz S, Knauth M, Mohr A, Wildemann B, Sommer C, Storch-Hagenlocher B (2001) Acute disseminated encephalomyelitis (ADEM). Nervenarzt 72:241–254PubMedCrossRef Schwarz S, Knauth M, Mohr A, Wildemann B, Sommer C, Storch-Hagenlocher B (2001) Acute disseminated encephalomyelitis (ADEM). Nervenarzt 72:241–254PubMedCrossRef
22.
Zurück zum Zitat Singh S, Alexander M, Korah IP (1999) Acute disseminated encephalomyelitis: MR imaging features. AJR Am J Roentgenol 173:1101–1107PubMedCrossRef Singh S, Alexander M, Korah IP (1999) Acute disseminated encephalomyelitis: MR imaging features. AJR Am J Roentgenol 173:1101–1107PubMedCrossRef
23.
Zurück zum Zitat Sonneville R, Klein IF, Wolff M (2010) Update on investigation and management of postinfectious encephalitis. Current Opinion in Neurology 23:300–304PubMedCrossRef Sonneville R, Klein IF, Wolff M (2010) Update on investigation and management of postinfectious encephalitis. Current Opinion in Neurology 23:300–304PubMedCrossRef
24.
Zurück zum Zitat Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N (1993) Involvement of cytokines in N-methyl-N’-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol 33:358–362PubMedCrossRef Sugita K, Suzuki N, Shimizu N, Takanashi J, Ishii M, Niimi N (1993) Involvement of cytokines in N-methyl-N’-nitro-N-nitrosoguanidine-induced plasminogen activator activity in acute disseminated encephalomyelitis and multiple sclerosis lymphocytes. Eur Neurol 33:358–362PubMedCrossRef
25.
Zurück zum Zitat Tenembaum S, Chamoles N, Fejerman N (2002) Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 59:1224–1231PubMedCrossRef Tenembaum S, Chamoles N, Fejerman N (2002) Acute disseminated encephalomyelitis: a long-term follow-up study of 84 pediatric patients. Neurology 59:1224–1231PubMedCrossRef
26.
Zurück zum Zitat Tenembaum S, Chitnis T, Ness J, Hahn JS (2007) Acute disseminated encephalomyelitis. Neurology 68(2):23–S36 (for the International Pediatric MS Study Group)CrossRef Tenembaum S, Chitnis T, Ness J, Hahn JS (2007) Acute disseminated encephalomyelitis. Neurology 68(2):23–S36 (for the International Pediatric MS Study Group)CrossRef
27.
Zurück zum Zitat van der Knaap MS, Valk J (1995) Magnetic resonance of myelin, myelination, and myelin disorders, 2. Aufl. Springer, Berlin, Heidelberg, New YorkCrossRef van der Knaap MS, Valk J (1995) Magnetic resonance of myelin, myelination, and myelin disorders, 2. Aufl. Springer, Berlin, Heidelberg, New YorkCrossRef
28.
Zurück zum Zitat Zettl UK, Lehmitz R, Mix E (2003) Klinische Liquordiagnostik. de Gruyter, Berlin, New York Zettl UK, Lehmitz R, Mix E (2003) Klinische Liquordiagnostik. de Gruyter, Berlin, New York
29.
Zurück zum Zitat Barnett MH, Prineas JW, Buckland ME, Parratt JDE, Pollard JD (2012) Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler J 18:108–112CrossRef Barnett MH, Prineas JW, Buckland ME, Parratt JDE, Pollard JD (2012) Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler J 18:108–112CrossRef
30.
Zurück zum Zitat Costanzi C, Matiello M, Lucchinett CFI, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A (2011) Azathioprine Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659–666PubMedCrossRef Costanzi C, Matiello M, Lucchinett CFI, Weinshenker BG, Pittock SJ, Mandrekar J, Thapa P, McKeon A (2011) Azathioprine Tolerability, efficacy, and predictors of benefit in neuromyelitis optica. Neurology 77:659–666PubMedCrossRef
31.
Zurück zum Zitat Filippi M, Rocca MA (2004) MR imaging of Devic’s neuromyelitis optica. Neurol Sci 25(Suppl 4):371–373CrossRef Filippi M, Rocca MA (2004) MR imaging of Devic’s neuromyelitis optica. Neurol Sci 25(Suppl 4):371–373CrossRef
32.
Zurück zum Zitat Freitas E, Guimaraes J (2014) Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatol Int 22 (Epub ahead of print) Freitas E, Guimaraes J (2014) Neuromyelitis optica spectrum disorders associated with other autoimmune diseases. Rheumatol Int 22 (Epub ahead of print)
33.
Zurück zum Zitat Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BAC (2008) Treatment of Neuromyelitis Optica with Rituximab Retrospective Analysis of 25 Patients. Arch Neurol 65:1443–1448PubMedCrossRef Jacob A, Weinshenker BG, Violich I, McLinskey N, Krupp L, Fox RJ, Wingerchuk DM, Boggild M, Constantinescu CS, Miller A, De Angelis T, Matiello M, Cree BAC (2008) Treatment of Neuromyelitis Optica with Rituximab Retrospective Analysis of 25 Patients. Arch Neurol 65:1443–1448PubMedCrossRef
34.
Zurück zum Zitat Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ (2009) Treatment of Neuromyelitis Optica with Mycophenolate Mofetil. Retrospective Analysis of 24 Patients. Arch Neurol 66:1128–1133PubMedCrossRef Jacob A, Matiello M, Weinshenker BG, Wingerchuk DM, Lucchinetti CF, Shuster E, Carter J, Keegan BM, Kantarci OH, Pittock SJ (2009) Treatment of Neuromyelitis Optica with Mycophenolate Mofetil. Retrospective Analysis of 24 Patients. Arch Neurol 66:1128–1133PubMedCrossRef
35.
Zurück zum Zitat Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild MM (2012) Does natalizumab therapy worsen neuromyelitis optica? Neurology 79:1065–1066PubMedCrossRef Jacob A, Hutchinson M, Elsone L, Kelly S, Ali R, Saukans I, Tubridy N, Boggild MM (2012) Does natalizumab therapy worsen neuromyelitis optica? Neurology 79:1065–1066PubMedCrossRef
36.
Zurück zum Zitat Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383–392PubMedCrossRef Jarius S, Wildemann B (2010) AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 6:383–392PubMedCrossRef
37.
Zurück zum Zitat Jarius S, Wildemann B (2013) Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 23:661–683PubMedCrossRef Jarius S, Wildemann B (2013) Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol 23:661–683PubMedCrossRef
39.
Zurück zum Zitat Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202–214PubMed Jarius S, Paul F, Franciotta D, Waters P, Zipp F, Hohlfeld R, Vincent A, Wildemann B (2008) Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat Clin Pract Neurol 4:202–214PubMed
40.
Zurück zum Zitat Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52–56PubMedCrossRef Jarius S, Probst C, Borowski K, Franciotta D, Wildemann B, Stoecker W, Wandinger KP (2010) Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 291:52–56PubMedCrossRef
41.
Zurück zum Zitat Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, Rommer P, Mader S, Kleiter I, Reindl M, Akman-Demir G, Seifert-Held T, Kristoferitsch W, Melms A, Wandinger KP, Wildemann B (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 17:1067–1073PubMedCrossRef Jarius S, Jacobi C, de Seze J, Zephir H, Paul F, Franciotta D, Rommer P, Mader S, Kleiter I, Reindl M, Akman-Demir G, Seifert-Held T, Kristoferitsch W, Melms A, Wandinger KP, Wildemann B (2011) Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 17:1067–1073PubMedCrossRef
42.
Zurück zum Zitat Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamasch R, Rommer P, Kleiten I, Stich O, Reuss R, Rauer S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W, Wildemann B (2011) Cerebrospinal fluid findings in aquaporin-4 positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci 306:82–90PubMedCrossRef Jarius S, Paul F, Franciotta D, Ruprecht K, Ringelstein M, Bergamasch R, Rommer P, Kleiten I, Stich O, Reuss R, Rauer S, Zettl UK, Wandinger KP, Melms A, Aktas O, Kristoferitsch W, Wildemann B (2011) Cerebrospinal fluid findings in aquaporin-4 positive neuromyelitis optica: Results from 211 lumbar punctures. J Neurol Sci 306:82–90PubMedCrossRef
43.
Zurück zum Zitat Jarius S, Paul F, Franciotta D, de Seze J, Munch C, Salvetti M, Ruprecht K, Liebetrau M, Wandinger KP, Akman-Demir G, Melms A, Kristoferitsch W, Wildemann B (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 18:1135–1143PubMedCrossRef Jarius S, Paul F, Franciotta D, de Seze J, Munch C, Salvetti M, Ruprecht K, Liebetrau M, Wandinger KP, Akman-Demir G, Melms A, Kristoferitsch W, Wildemann B (2012) Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature. Mult Scler 18:1135–1143PubMedCrossRef
44.
Zurück zum Zitat Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, Ringelstein M, Aktas O, Kristoferitsch W, Wildemann B (2012) Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 320:32–37PubMedCrossRef Jarius S, Franciotta D, Paul F, Bergamaschi R, Rommer PS, Ruprecht K, Ringelstein M, Aktas O, Kristoferitsch W, Wildemann B (2012) Testing for antibodies to human aquaporin-4 by ELISA: sensitivity, specificity, and direct comparison with immunohistochemistry. J Neurol Sci 320:32–37PubMedCrossRef
45.
46.
Zurück zum Zitat Kim SH, Huh SY, Lee SJ, Joung AR, Kim HJ (2013) 5-Year Follow-up of Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 70:1110–1117PubMedCrossRef Kim SH, Huh SY, Lee SJ, Joung AR, Kim HJ (2013) 5-Year Follow-up of Rituximab Treatment in Patients with Neuromyelitis Optica Spectrum Disorder. JAMA Neurol 70:1110–1117PubMedCrossRef
47.
Zurück zum Zitat Kimbrough D, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, Marignier R, Nakashima I, Palace J, de Seze J, Stuve O, Tenembaum SN, Traboulsee A, Waubant E, Weinshenker BG, Wingerchuk DM (2012) Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord 1:80–87 (with the GJCF-CC&BR)CrossRef Kimbrough D, Fujihara K, Jacob A, Lana-Peixoto MA, Leite MI, Levy M, Marignier R, Nakashima I, Palace J, de Seze J, Stuve O, Tenembaum SN, Traboulsee A, Waubant E, Weinshenker BG, Wingerchuk DM (2012) Treatment of neuromyelitis optica: Review and recommendations. Mult Scler Relat Disord 1:80–87 (with the GJCF-CC&BR)CrossRef
48.
Zurück zum Zitat Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMedCrossRef Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112PubMedCrossRef
49.
Zurück zum Zitat Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477PubMedPubMedCentralCrossRef Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 202:473–477PubMedPubMedCentralCrossRef
50.
Zurück zum Zitat Lim BC, Hwang H, Kim KJ, Cheon JE, Kim IO, Kim HJ, Chae JH (2011) Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult Scler 17:67–73PubMedCrossRef Lim BC, Hwang H, Kim KJ, Cheon JE, Kim IO, Kim HJ, Chae JH (2011) Relapsing demyelinating CNS disease in a Korean pediatric population: multiple sclerosis versus neuromyelitis optica. Mult Scler 17:67–73PubMedCrossRef
51.
Zurück zum Zitat Mandler RN, Davis LE, Jeffery DR, Kornfeld M (2002) Devic’s neuromyelitis optica: a clinicpathological study of 8 patients. Ann Neurol 34:162–168CrossRef Mandler RN, Davis LE, Jeffery DR, Kornfeld M (2002) Devic’s neuromyelitis optica: a clinicpathological study of 8 patients. Ann Neurol 34:162–168CrossRef
52.
Zurück zum Zitat Matthews L, Marasco R, Jenkinson M, Küker W, Luppe S, Leite MI, Giorgio A, De Stefano N, Robertson N, Johansen-Berg H, Evangelou N, Palace J (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80:1330–1337PubMedPubMedCentralCrossRef Matthews L, Marasco R, Jenkinson M, Küker W, Luppe S, Leite MI, Giorgio A, De Stefano N, Robertson N, Johansen-Berg H, Evangelou N, Palace J (2013) Distinction of seropositive NMO spectrum disorder and MS brain lesion distribution. Neurology 80:1330–1337PubMedPubMedCentralCrossRef
53.
Zurück zum Zitat Min HJ, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J 18:113–115CrossRef Min HJ, Kim BJ, Lee KH (2012) Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult Scler J 18:113–115CrossRef
54.
Zurück zum Zitat Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta Treatment in Neuromyelitis Optica. Increase in Relapses and Aquaporin 4 Antibody Titers. Arch Neurol 67:1016–1017PubMedCrossRef Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta Treatment in Neuromyelitis Optica. Increase in Relapses and Aquaporin 4 Antibody Titers. Arch Neurol 67:1016–1017PubMedCrossRef
55.
Zurück zum Zitat Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG (2006) Brain Abnormalities in Neuromyelitis Optica. Arch Neurol 63:390–396PubMedCrossRef Pittock SJ, Lennon VA, Krecke K, Wingerchuk DM, Lucchinetti CF, Weinshenker BG (2006) Brain Abnormalities in Neuromyelitis Optica. Arch Neurol 63:390–396PubMedCrossRef
56.
Zurück zum Zitat Qian P, Cross AH, Naismith RT (2011) Lack of Response to Monoclonal Antibody Therapy in Neuromyelitis Optica.Author Affiliations: Department of Neurology, Washington University, St Louis, Missouri. Arch Neurol 68:1207–1209PubMedPubMedCentralCrossRef Qian P, Cross AH, Naismith RT (2011) Lack of Response to Monoclonal Antibody Therapy in Neuromyelitis Optica.Author Affiliations: Department of Neurology, Washington University, St Louis, Missouri. Arch Neurol 68:1207–1209PubMedPubMedCentralCrossRef
57.
Zurück zum Zitat Ringelstein M, Metz I, Ruprecht K, Koch A.; Rappold J, Ingwersen, Mathys C, Jarius S, Brueck W, Hartung HP, Paul F, Aktas O (2014) Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler J 20: 882–888 Ringelstein M, Metz I, Ruprecht K, Koch A.; Rappold J, Ingwersen, Mathys C, Jarius S, Brueck W, Hartung HP, Paul F, Aktas O (2014) Contribution of spinal cord biopsy to diagnosis of aquaporin-4 antibody positive neuromyelitis optica spectrum disorder. Mult Scler J 20: 882–888
58.
Zurück zum Zitat Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kumpfel T (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16PubMedCrossRef Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kumpfel T (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16PubMedCrossRef
59.
Zurück zum Zitat Wildemann B, Jarius S, Paul F (2012) Neuromyelitis optica. Akt Neurol 39:33–41CrossRef Wildemann B, Jarius S, Paul F (2012) Neuromyelitis optica. Akt Neurol 39:33–41CrossRef
60.
61.
Zurück zum Zitat Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815PubMedCrossRef Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6:805–815PubMedCrossRef
62.
Zurück zum Zitat Comi G (2004) Multiple sclerosis: pseudotumoral forms. Neurol Sci 25(Suppl 4):374–379CrossRef Comi G (2004) Multiple sclerosis: pseudotumoral forms. Neurol Sci 25(Suppl 4):374–379CrossRef
63.
Zurück zum Zitat Hu W, Lucchinetti CF (2009) The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 31:439–453PubMedCrossRef Hu W, Lucchinetti CF (2009) The pathological spectrum of CNS inflammatory demyelinating diseases. Semin Immunopathol 31:439–453PubMedCrossRef
64.
Zurück zum Zitat Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Brück W (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775PubMedPubMedCentralCrossRef Lucchinetti CF, Gavrilova RH, Metz I, Parisi JE, Scheithauer BW, Weigand S, Thomsen K, Mandrekar J, Altintas A, Erickson BJ, König F, Giannini C, Lassmann H, Linbo L, Pittock SJ, Brück W (2008) Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis. Brain 131:1759–1775PubMedPubMedCentralCrossRef
65.
Zurück zum Zitat Mehler MF, Rabinowich L (1989) Inflammatory myelinoclastic diffuse sclerosis (Schilder’s disease): neuroradiologic findings. AJNR 10:176–180PubMed Mehler MF, Rabinowich L (1989) Inflammatory myelinoclastic diffuse sclerosis (Schilder’s disease): neuroradiologic findings. AJNR 10:176–180PubMed
66.
Zurück zum Zitat Poser CM, Goutieres F, Caroentier MA, Aicardi J (1986) Schilder’s myelinoclastic diffuse sclerosis. Pediatrics 77:107–112PubMed Poser CM, Goutieres F, Caroentier MA, Aicardi J (1986) Schilder’s myelinoclastic diffuse sclerosis. Pediatrics 77:107–112PubMed
67.
Zurück zum Zitat Rahmlow MR, Kantarci O (2014) Fulminant Demyelinating Diseases. The Neurohospitalist 3:81–91CrossRef Rahmlow MR, Kantarci O (2014) Fulminant Demyelinating Diseases. The Neurohospitalist 3:81–91CrossRef
68.
Zurück zum Zitat Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blöcker IM, Bahtz R, Komorowski L, Stöcker W, Kastrup A, Kuthe M, Meinck (2014) Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 82:1521–1528PubMedCrossRef Balint B, Jarius S, Nagel S, Haberkorn U, Probst C, Blöcker IM, Bahtz R, Komorowski L, Stöcker W, Kastrup A, Kuthe M, Meinck (2014) Progressive encephalomyelitis with rigidity and myoclonus: a new variant with DPPX antibodies. Neurology 82:1521–1528PubMedCrossRef
69.
Zurück zum Zitat Bataller L, Galiano R, Garcia-Escrig M, Martinez B, Sevilla T, Blasco R, Vilchez JJ, Dalmau J (2010) Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 74:265–267PubMedPubMedCentralCrossRef Bataller L, Galiano R, Garcia-Escrig M, Martinez B, Sevilla T, Blasco R, Vilchez JJ, Dalmau J (2010) Reversible paraneoplastic limbic encephalitis associated with antibodies to the AMPA receptor. Neurology 74:265–267PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Baumgartner A, Rauer S, Mader I (2013) Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol 260:2744–2753PubMedCrossRef Baumgartner A, Rauer S, Mader I (2013) Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol 260:2744–2753PubMedCrossRef
71.
Zurück zum Zitat Boronat A, Sabater L, Saiz A, Dalmau J, Graus F (2011) GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 76:795–800PubMedPubMedCentralCrossRef Boronat A, Sabater L, Saiz A, Dalmau J, Graus F (2011) GABA(B) receptor antibodies in limbic encephalitis and anti-GAD-associated neurologic disorders. Neurology 76:795–800PubMedPubMedCentralCrossRef
72.
Zurück zum Zitat Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F, Rudy B, Dalmau J (2013) Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 73:120–128PubMedCrossRef Boronat A, Gelfand JM, Gresa-Arribas N, Jeong HY, Walsh M, Roberts K, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R, Graus F, Rudy B, Dalmau J (2013) Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol 73:120–128PubMedCrossRef
73.
Zurück zum Zitat Carr I (1982) The Ophelia syndrome: memory loss in Hodgkin`s disease. Lancet 10:844–845CrossRef Carr I (1982) The Ophelia syndrome: memory loss in Hodgkin`s disease. Lancet 10:844–845CrossRef
74.
Zurück zum Zitat Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, Lang B, Pettingill P, Carr A, Sheerin UM, Press R, Lunn MP, Lim M, Maddison P, Meinck HM, Vandenberghe W, Vincent A (2014) Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 137:2178–2192PubMedPubMedCentralCrossRef Carvajal-Gonzalez A, Leite MI, Waters P, Woodhall M, Coutinho E, Balint B, Lang B, Pettingill P, Carr A, Sheerin UM, Press R, Lunn MP, Lim M, Maddison P, Meinck HM, Vandenberghe W, Vincent A (2014) Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes. Brain 137:2178–2192PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36PubMedPubMedCentralCrossRef Dalmau J, Tüzün E, Wu HY, Masjuan J, Rossi JE, Voloschin A, Baehring JM, Shimazaki H, Koide R, King D, Mason W, Sansing LH, Dichter MA, Rosenfeld MR, Lynch DR (2007) Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol 61:25–36PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with NMDAR encephalitis. Lancet Neurol 10:63–74PubMedPubMedCentralCrossRef Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R (2011) Clinical experience and laboratory investigations in patients with NMDAR encephalitis. Lancet Neurol 10:63–74PubMedPubMedCentralCrossRef
78.
Zurück zum Zitat Darnell RB, Posner JB (2011) Paraneoplastic syndromes. Oxford University Press, Oxford, New York Darnell RB, Posner JB (2011) Paraneoplastic syndromes. Oxford University Press, Oxford, New York
79.
Zurück zum Zitat Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J (2009) Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 66:11–18PubMedPubMedCentralCrossRef Florance NR, Davis RL, Lam C, Szperka C, Zhou L, Ahmad S, Campen CJ, Moss H, Peter N, Gleichman AJ, Glaser CA, Lynch DR, Rosenfeld MR, Dalmau J (2009) Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol 66:11–18PubMedPubMedCentralCrossRef
80.
Zurück zum Zitat Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJ, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140PubMedPubMedCentralCrossRef Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, Honnorat J, Smitt PS, Vedeler C, Verschuuren JJ, Vincent A, Voltz R (2004) Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry 75:1135–1140PubMedPubMedCentralCrossRef
81.
Zurück zum Zitat Graus F, Boronat A, Xifró X, Boix M, Svigelj V, Garcia A, Palomino A, Sabater L, Alberch J, Saiz A (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74:857–859PubMedCrossRef Graus F, Boronat A, Xifró X, Boix M, Svigelj V, Garcia A, Palomino A, Sabater L, Alberch J, Saiz A (2010) The expanding clinical profile of anti-AMPA receptor encephalitis. Neurology 74:857–859PubMedCrossRef
82.
Zurück zum Zitat Gres-Arribas N, Titulaer MJ, Torrents A, Aquilar E, McCracken L, Leypoldt F, Gleichman AJ, Balice-Gordon R, Rosenfeld MR, Lynch D, Graus F, Dalmau J (2014) Antibody titers at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 13:167–177CrossRef Gres-Arribas N, Titulaer MJ, Torrents A, Aquilar E, McCracken L, Leypoldt F, Gleichman AJ, Balice-Gordon R, Rosenfeld MR, Lynch D, Graus F, Dalmau J (2014) Antibody titers at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol 13:167–177CrossRef
83.
Zurück zum Zitat Höftberger R, Tutulaer MJ, Sabater L, Dome B, Rózsás A, Hoda MA, Laszlo V, Ankersmit HJ, Harms L, Boyero S, de Felipe A, Saiz A, Dalmau J, Graus F (2013) Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 81:1500–1506PubMedPubMedCentralCrossRef Höftberger R, Tutulaer MJ, Sabater L, Dome B, Rózsás A, Hoda MA, Laszlo V, Ankersmit HJ, Harms L, Boyero S, de Felipe A, Saiz A, Dalmau J, Graus F (2013) Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Neurology 81:1500–1506PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan`s syndrome and acquired neuromyotonia. Brain 133:2734–2748PubMedPubMedCentralCrossRef Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, Peles E, Buckley C, Lang B, Vincent A (2010) Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan`s syndrome and acquired neuromyotonia. Brain 133:2734–2748PubMedPubMedCentralCrossRef
85.
Zurück zum Zitat Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, Zagami SA, Bleasel A, Somerville ER, Smith SM, Vincent A (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69:892–900PubMedCrossRef Irani SR, Michell AW, Lang B, Pettingill P, Waters P, Johnson MR, Schott JM, Armstrong RJ, Zagami SA, Bleasel A, Somerville ER, Smith SM, Vincent A (2011) Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Ann Neurol 69:892–900PubMedCrossRef
86.
Zurück zum Zitat Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, Waters P, Thomas A, Voets NL, Cardoso MJ, Cash DM, Manning EN, Lang B, Smith SJ, Vincent A, Johnson MR (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136:3151–3162PubMedCrossRef Irani SR, Stagg CJ, Schott JM, Rosenthal CR, Schneider SA, Pettingill P, Waters P, Thomas A, Voets NL, Cardoso MJ, Cash DM, Manning EN, Lang B, Smith SJ, Vincent A, Johnson MR (2013) Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype. Brain 136:3151–3162PubMedCrossRef
87.
Zurück zum Zitat Jarius S, Hoffmann L, Clover L, Vincent A, Voltz R (2008) CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci 268:74–77PubMedCrossRef Jarius S, Hoffmann L, Clover L, Vincent A, Voltz R (2008) CSF findings in patients with voltage gated potassium channel antibody associated limbic encephalitis. J Neurol Sci 268:74–77PubMedCrossRef
88.
Zurück zum Zitat Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B (2012) Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 114:331–335PubMedCrossRef Jarius S, Wandinger KP, Borowski K, Stoecker W, Wildemann B (2012) Antibodies to CV2/CRMP5 in neuromyelitis optica-like disease: case report and review of the literature. Clin Neurol Neurosurg 114:331–335PubMedCrossRef
89.
Zurück zum Zitat Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9:776–785PubMedPubMedCentralCrossRef Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, Cowell JK, Dalmau J (2010) Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol 9:776–785PubMedPubMedCentralCrossRef
90.
91.
Zurück zum Zitat Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Gutman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurology 9:67–76PubMedCrossRef Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J, Friedman D, Skeen MB, Grisold W, Kimura A, Ohta K, Iizuka T, Gutman M, Graus F, Moss SJ, Balice-Gordon R, Dalmau J (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurology 9:67–76PubMedCrossRef
92.
Zurück zum Zitat Lancaster E, Martinez-Hernandez E, Dalmau J (2011) Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77:179–189PubMedPubMedCentralCrossRef Lancaster E, Martinez-Hernandez E, Dalmau J (2011) Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology 77:179–189PubMedPubMedCentralCrossRef
93.
Zurück zum Zitat Leypoldt F (2012) Paraneoplastische Syndrom. In: Diener HC, Weimar V (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie.. Thieme, Stuttgart Leypoldt F (2012) Paraneoplastische Syndrom. In: Diener HC, Weimar V (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie.. Thieme, Stuttgart
95.
Zurück zum Zitat Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, Dalmau J, Gerloff C, Lewerenz J (2012) Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry 83:681–686PubMedPubMedCentralCrossRef Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T, Dalmau J, Gerloff C, Lewerenz J (2012) Fluorodeoxyglucose positron emission tomography in anti-N-methyl-D-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry 83:681–686PubMedPubMedCentralCrossRef
96.
Zurück zum Zitat Mat A, Adler H, Merwick A, Chadwick G, Gullo G, Dalmau JO, Tubridy N (2013) Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology 80:1349–1350PubMedPubMedCentralCrossRef Mat A, Adler H, Merwick A, Chadwick G, Gullo G, Dalmau JO, Tubridy N (2013) Ophelia syndrome with metabotropic glutamate receptor 5 antibodies in CSF. Neurology 80:1349–1350PubMedPubMedCentralCrossRef
97.
Zurück zum Zitat Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, McCracken L, Martinez-Hernandez E, Mason WP, Kruer MC, Ritacco DG, Grisold W, Meaney BF, Alcalá C, Sillevis-Smitt P, Titulaer MJ, Balice-Gordon R, Graus F, Dalmau J (2014) Encephalitis with refractory seizures, status epilepticus, and antibodies to the GAGAA receptor: a case series, characterisation of the antigen, analysis of the efffects of antibodies. Lancet Neurology 13:276–286PubMedCrossRef Petit-Pedrol M, Armangue T, Peng X, Bataller L, Cellucci T, Davis R, McCracken L, Martinez-Hernandez E, Mason WP, Kruer MC, Ritacco DG, Grisold W, Meaney BF, Alcalá C, Sillevis-Smitt P, Titulaer MJ, Balice-Gordon R, Graus F, Dalmau J (2014) Encephalitis with refractory seizures, status epilepticus, and antibodies to the GAGAA receptor: a case series, characterisation of the antigen, analysis of the efffects of antibodies. Lancet Neurology 13:276–286PubMedCrossRef
98.
99.
Zurück zum Zitat Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 27:1094–1100CrossRef Schmitt SE, Pargeon K, Frechette ES, Hirsch LJ, Dalmau J, Friedman D (2012) Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology 27:1094–1100CrossRef
100.
Zurück zum Zitat Stich O, Rauer S (2014) Paraneoplastic neurological syndromes and autoimmune encephalitis. Nervenarzt 85:499–501CrossRef Stich O, Rauer S (2014) Paraneoplastic neurological syndromes and autoimmune encephalitis. Nervenarzt 85:499–501CrossRef
101.
Zurück zum Zitat Stöcker W, Saschenbrecher S, Rentzsch K, Komorowski L, Probst C (2013) Autoantibody diagnostics in neurology using native and recombinant antigenic substrates. Nervenarzt 84:471–476PubMedCrossRef Stöcker W, Saschenbrecher S, Rentzsch K, Komorowski L, Probst C (2013) Autoantibody diagnostics in neurology using native and recombinant antigenic substrates. Nervenarzt 84:471–476PubMedCrossRef
102.
Zurück zum Zitat Titulaer MJ, Lang B, Verschuuren JJ (2011) Lambert-Eaton myasthenic syndrome: from clinical characterisics to therapeutic strategies. Lancet Neurology 10:1098–1107PubMedCrossRef Titulaer MJ, Lang B, Verschuuren JJ (2011) Lambert-Eaton myasthenic syndrome: from clinical characterisics to therapeutic strategies. Lancet Neurology 10:1098–1107PubMedCrossRef
103.
Zurück zum Zitat Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PAE, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJGM (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 18:19–e3PubMedCrossRef Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, Grisold W, Honnorat J, Sillevis Smitt PAE, Tanasescu R, Vedeler CA, Voltz R, Verschuuren JJGM (2011) Screening for tumours in paraneoplastic syndromes: report of an EFNS Task Force. Eur J Neurol 18:19–e3PubMedCrossRef
104.
Zurück zum Zitat Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aquilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis. An observational cohort study. Lancet Neurol 12:157–165PubMedPubMedCentralCrossRef Titulaer MJ, McCracken L, Gabilondo I, Armangue T, Glaser C, Iizuka T, Honig LS, Benseler SM, Kawachi I, Martinez-Hernandez E, Aquilar E, Gresa-Arribas N, Ryan-Florance N, Torrents A, Saiz A, Rosenfeld MR, Balice-Gordon R, Graus F, Dalmau J (2013) Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis. An observational cohort study. Lancet Neurol 12:157–165PubMedPubMedCentralCrossRef
105.
Zurück zum Zitat Vincent A, Bien CG, Irani SR, Waters P (2011) Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 10:759–772PubMedCrossRef Vincent A, Bien CG, Irani SR, Waters P (2011) Autoantibodies associated with diseases of the CNS: new developments and future challenges. Lancet Neurol 10:759–772PubMedCrossRef
106.
Zurück zum Zitat Vitaliani R, Mason W, Ances B, Zwerling T, Jiang Z, Dalmau J (2005) Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 58:594–604PubMedPubMedCentralCrossRef Vitaliani R, Mason W, Ances B, Zwerling T, Jiang Z, Dalmau J (2005) Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 58:594–604PubMedPubMedCentralCrossRef
107.
Zurück zum Zitat Arnaud L, Haroche J, Malek Z et al (2009) Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 60:1193–1200PubMedCrossRef Arnaud L, Haroche J, Malek Z et al (2009) Is (18)F-fluorodeoxyglucose positron emission tomography scanning a reliable way to assess disease activity in Takayasu arteritis? Arthritis Rheum 60:1193–1200PubMedCrossRef
108.
Zurück zum Zitat Aviv RI, Benseler SM, DeVeber G et al (2007) Angiography of primary central nervous system angiitis of childhood: conventional angiography versus magnetic resonance angiography at presentation. Am J Neuroradiol 28:9–15PubMedCrossRef Aviv RI, Benseler SM, DeVeber G et al (2007) Angiography of primary central nervous system angiitis of childhood: conventional angiography versus magnetic resonance angiography at presentation. Am J Neuroradiol 28:9–15PubMedCrossRef
109.
Zurück zum Zitat Basu N, Watts R, Bajema I et al (2010) EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69:1744–1750PubMedCrossRef Basu N, Watts R, Bajema I et al (2010) EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis. Ann Rheum Dis 69:1744–1750PubMedCrossRef
111.
Zurück zum Zitat Berlit P, Krämer M (2014) Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls. Clin Exp Immunol 175:419–424PubMedPubMedCentralCrossRef Berlit P, Krämer M (2014) Cerebral vasculitis in adults: what are the steps in order to establish the diagnosis? Red flags and pitfalls. Clin Exp Immunol 175:419–424PubMedPubMedCentralCrossRef
112.
Zurück zum Zitat Berlit P, Baumgärtel M, Hellmich B, Krämer M et al (2012) Zerebrale Vaskulitis. In: Diener HC, Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie.. Thieme, Stuttgart, New York Berlit P, Baumgärtel M, Hellmich B, Krämer M et al (2012) Zerebrale Vaskulitis. In: Diener HC, Kommission Leitlinien der Deutschen Gesellschaft für Neurologie (Hrsg) Leitlinien für Diagnostik und Therapie in der Neurologie.. Thieme, Stuttgart, New York
113.
Zurück zum Zitat Gonzalez-Gay MA (2005) The diagnosis and management of patients with giant cell arteritis. J Rheumatol 32:1186–1188PubMed Gonzalez-Gay MA (2005) The diagnosis and management of patients with giant cell arteritis. J Rheumatol 32:1186–1188PubMed
114.
Zurück zum Zitat Hajj-Ali RA, Singhal AB, Benseler S et al (2011) Primary angiitis of the CNS. Lancet Neurol 10:561–572PubMedCrossRef Hajj-Ali RA, Singhal AB, Benseler S et al (2011) Primary angiitis of the CNS. Lancet Neurol 10:561–572PubMedCrossRef
115.
Zurück zum Zitat Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11PubMedCrossRef Jennette JC, Falk RJ, Bacon PA et al (2013) 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1–11PubMedCrossRef
116.
Zurück zum Zitat Krämer M, Berlit P (2010) Primary central nervous system vasculitis and moyamoya disease: similarities and differences. J Neurol 257:816–819CrossRef Krämer M, Berlit P (2010) Primary central nervous system vasculitis and moyamoya disease: similarities and differences. J Neurol 257:816–819CrossRef
117.
Zurück zum Zitat Krämer M, Berlit P (2010) Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases. Rheumatol Int 30:1471–1476CrossRef Krämer M, Berlit P (2010) Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases. Rheumatol Int 30:1471–1476CrossRef
118.
Zurück zum Zitat Krämer M, Berlit P (2011) Primary central nervous system vasculitis: clinical experiences with 21 new European cases. Rheumatol Int 31:463–472CrossRef Krämer M, Berlit P (2011) Primary central nervous system vasculitis: clinical experiences with 21 new European cases. Rheumatol Int 31:463–472CrossRef
119.
Zurück zum Zitat Krämer M, Berlit P (2011) Reversible cerebral vasoconstriction syndrome vs cerebral vasculitis? On the importance and difficulty of differentiating. Nervenarzt 82:504–505 (500, 502)CrossRef Krämer M, Berlit P (2011) Reversible cerebral vasoconstriction syndrome vs cerebral vasculitis? On the importance and difficulty of differentiating. Nervenarzt 82:504–505 (500, 502)CrossRef
120.
Zurück zum Zitat Krämer M, Diehl RR, Diesner F et al (2012) Differential diagnosis between cerebral ischemia, focal seizures and limb shaking TIAs in moyamoya disease. Br J Neurosurg 26:896–898CrossRef Krämer M, Diehl RR, Diesner F et al (2012) Differential diagnosis between cerebral ischemia, focal seizures and limb shaking TIAs in moyamoya disease. Br J Neurosurg 26:896–898CrossRef
121.
Zurück zum Zitat Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, European Vasculitis Study Group (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68(3):318–323PubMedCrossRef Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, European Vasculitis Study Group (2009) EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 68(3):318–323PubMedCrossRef
122.
Zurück zum Zitat Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, European Vasculitis Study Group (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317PubMedCrossRef Mukhtyar C, Guillevin L, Cid MC, Dasgupta B, de Groot K, Gross W, Hauser T, Hellmich B, Jayne D, Kallenberg CG, Merkel PA, Raspe H, Salvarani C, Scott DG, Stegeman C, Watts R, Westman K, Witter J, Yazici H, Luqmani R, European Vasculitis Study Group (2009) EULAR recommendations for the management of primary small and medium vessel vasculitis. Ann Rheum Dis 68(3):310–317PubMedCrossRef
123.
Zurück zum Zitat Obusez EC, Hui F, Hajj-Ali RA et al (2014) High-resolution MRI vessel wall imaging: spatial and temporal patterns of reversible cerebral vasoconstriction syndrome and central nervous system vasculitis. AJNR Am J Neuroradiol 35:1527–1532PubMedCrossRef Obusez EC, Hui F, Hajj-Ali RA et al (2014) High-resolution MRI vessel wall imaging: spatial and temporal patterns of reversible cerebral vasoconstriction syndrome and central nervous system vasculitis. AJNR Am J Neuroradiol 35:1527–1532PubMedCrossRef
124.
Zurück zum Zitat Pfefferkorn T, Linn J, Habs M et al (2013) Black blood MRI in suspected large artery primary angiitis of the central nervous system. J Neuroimaging 23:379–383PubMedCrossRef Pfefferkorn T, Linn J, Habs M et al (2013) Black blood MRI in suspected large artery primary angiitis of the central nervous system. J Neuroimaging 23:379–383PubMedCrossRef
125.
Zurück zum Zitat Pipitone N, Versari A, Hunder GG, Salvarani C (2013) Role of imaging in the diagnosis of large and medium-sized vessel vasculitis. Rheum Dis Clin North Am 39:593–608PubMedCrossRef Pipitone N, Versari A, Hunder GG, Salvarani C (2013) Role of imaging in the diagnosis of large and medium-sized vessel vasculitis. Rheum Dis Clin North Am 39:593–608PubMedCrossRef
126.
Zurück zum Zitat Saam T, Habs M, Cyran CC et al (2010) New aspects of MRI for diagnostics of large vessel vasculitis and primary angiitis of the central nervous system. Radiologe 50:861–871PubMedCrossRef Saam T, Habs M, Cyran CC et al (2010) New aspects of MRI for diagnostics of large vessel vasculitis and primary angiitis of the central nervous system. Radiologe 50:861–871PubMedCrossRef
127.
Zurück zum Zitat Salvarani C (2003) Large vessel vasculitis. Clin Exp Rheumatol 21(6 Suppl 32):133–134 Salvarani C (2003) Large vessel vasculitis. Clin Exp Rheumatol 21(6 Suppl 32):133–134
128.
Zurück zum Zitat Salvarani C, Brown RD Jr., Calamia KT et al (2007) Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 62:442–451PubMedCrossRef Salvarani C, Brown RD Jr., Calamia KT et al (2007) Primary central nervous system vasculitis: analysis of 101 patients. Ann Neurol 62:442–451PubMedCrossRef
129.
Zurück zum Zitat Salvarani C, Brown RD Jr., Calamia KT et al (2008) Angiography-negative primary central nervous system vasculitis: a syndrome involving small cerebral vessels. Medicine (Baltimore) 87:264–271CrossRef Salvarani C, Brown RD Jr., Calamia KT et al (2008) Angiography-negative primary central nervous system vasculitis: a syndrome involving small cerebral vessels. Medicine (Baltimore) 87:264–271CrossRef
130.
Zurück zum Zitat TS Board of Directors and by the ERS Executive Committee (1999) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). February 1999. Am J Respir Crit Care Med 160:736–755CrossRef TS Board of Directors and by the ERS Executive Committee (1999) Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG). February 1999. Am J Respir Crit Care Med 160:736–755CrossRef
131.
Zurück zum Zitat Barnard J, Newman LS (2001) Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 13:84–91PubMedCrossRef Barnard J, Newman LS (2001) Sarcoidosis: immunology, rheumatic involvement, and therapeutics. Curr Opin Rheumatol 13:84–91PubMedCrossRef
132.
133.
Zurück zum Zitat Bolat S, Berding G, Dengler R, Stangel M, Trebst C (2009) Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 287:257–259PubMedCrossRef Bolat S, Berding G, Dengler R, Stangel M, Trebst C (2009) Fluorodeoxyglucose positron emission tomography (FDG-PET) is useful in the diagnosis of neurosarcoidosis. J Neurol Sci 287:257–259PubMedCrossRef
134.
Zurück zum Zitat Bunting PS, Szalai JP, Katic M (1987) Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem 20:213–219PubMedCrossRef Bunting PS, Szalai JP, Katic M (1987) Diagnostic aspects of angiotensin converting enzyme in pulmonary sarcoidosis. Clin Biochem 20:213–219PubMedCrossRef
135.
Zurück zum Zitat Christoforidis GA, Spickler EM, Recio MV, Mehta BM (1999) MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 20:655–669PubMed Christoforidis GA, Spickler EM, Recio MV, Mehta BM (1999) MR of CNS sarcoidosis: correlation of imaging features to clinical symptoms and response to treatment. AJNR Am J Neuroradiol 20:655–669PubMed
136.
Zurück zum Zitat Gascón-Bayarri J, Maná J, Martiínez-Yélamos S et al (2011) Neurosarcoidosis Report of 30 cases and a literature survey. European Journal of Internal Medicine 22:e125–e132PubMedCrossRef Gascón-Bayarri J, Maná J, Martiínez-Yélamos S et al (2011) Neurosarcoidosis Report of 30 cases and a literature survey. European Journal of Internal Medicine 22:e125–e132PubMedCrossRef
137.
Zurück zum Zitat Hayat GR, Walton TP, Smith KR Jr, Martin DS, Manepalli AN (2001) Solitary intramedullary neurosarcoidosis: role of MRI in early detection. J Neuroimaging 11:66–70PubMedCrossRef Hayat GR, Walton TP, Smith KR Jr, Martin DS, Manepalli AN (2001) Solitary intramedullary neurosarcoidosis: role of MRI in early detection. J Neuroimaging 11:66–70PubMedCrossRef
138.
Zurück zum Zitat Hershcovici T, Mekhmandorov S, Beigel Y, Hardoff R (2001) The value of Ga-67 scintigraphy in sarcoid myopathy. Clin Nucl Med 26:540–542PubMedCrossRef Hershcovici T, Mekhmandorov S, Beigel Y, Hardoff R (2001) The value of Ga-67 scintigraphy in sarcoid myopathy. Clin Nucl Med 26:540–542PubMedCrossRef
139.
Zurück zum Zitat Hoitsma E, Faber CG, Drent M, Sharma OP (2004) Neurosarcoidosis: a clinical dilemma. Lancet Neurol 3:397–407PubMedCrossRef Hoitsma E, Faber CG, Drent M, Sharma OP (2004) Neurosarcoidosis: a clinical dilemma. Lancet Neurol 3:397–407PubMedCrossRef
140.
Zurück zum Zitat Hoitsma E, Drent M, Sharma OP (2010) A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 16:472–479PubMedCrossRef Hoitsma E, Drent M, Sharma OP (2010) A pragmatic approach to diagnosing and treating neurosarcoidosis in the 21st century. Curr Opin Pulm Med 16:472–479PubMedCrossRef
141.
Zurück zum Zitat Kramers C, Deinum J (2003) Increased serum activity of angiotensin-converting enzyme (ACE): indication of sarcoidosis? A ‘Bayesian’ approach. Ned Tijdschr Geneeskd 147:473–476PubMed Kramers C, Deinum J (2003) Increased serum activity of angiotensin-converting enzyme (ACE): indication of sarcoidosis? A ‘Bayesian’ approach. Ned Tijdschr Geneeskd 147:473–476PubMed
142.
Zurück zum Zitat Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O (2003) Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med 14:237–243PubMedCrossRef Leclerc S, Myers RP, Moussalli J, Herson S, Poynard T, Benveniste O (2003) Sarcoidosis and interferon therapy: report of five cases and review of the literature. Eur J Intern Med 14:237–243PubMedCrossRef
143.
Zurück zum Zitat Nowak DA, Widenka DC (2001) Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 248:363–372PubMedCrossRef Nowak DA, Widenka DC (2001) Neurosarcoidosis: a review of its intracranial manifestation. J Neurol 248:363–372PubMedCrossRef
144.
Zurück zum Zitat Petereit H-F, Reske D, Tumani H, Jarius S, Leweke FM, Woitall D, Pfister H-W, Ruppert A (2010) Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 257:1855–1863PubMedCrossRef Petereit H-F, Reske D, Tumani H, Jarius S, Leweke FM, Woitall D, Pfister H-W, Ruppert A (2010) Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis. J Neurol 257:1855–1863PubMedCrossRef
145.
Zurück zum Zitat Reske D, Petereit HF, Heiss WD (2005) Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system – value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 112:207–213PubMedCrossRef Reske D, Petereit HF, Heiss WD (2005) Difficulties in the differentiation of chronic inflammatory diseases of the central nervous system – value of cerebrospinal fluid analysis and immunological abnormalities in the diagnosis. Acta Neurol Scand 112:207–213PubMedCrossRef
146.
Zurück zum Zitat Roberts SD, Wilkes DS, Burgett RA, Knox KS (2003) Refractory sarcoidosis responding to infliximab. Chest 124:2028–2031PubMedCrossRef Roberts SD, Wilkes DS, Burgett RA, Knox KS (2003) Refractory sarcoidosis responding to infliximab. Chest 124:2028–2031PubMedCrossRef
147.
Zurück zum Zitat Segal BM (2013) Neurosarcoidosis: diagnostic approaches and therapeutic strategies. Curr Opin Neurol 26:307–313PubMedCrossRef Segal BM (2013) Neurosarcoidosis: diagnostic approaches and therapeutic strategies. Curr Opin Neurol 26:307–313PubMedCrossRef
148.
Zurück zum Zitat Sohn HS, Kim EN, Park JM, Chung YA (2001) Muscular sarcoidosis: Ga-67 scintigraphy and magnetic resonance imaging. Clin Nucl Med 26:29–32PubMedCrossRef Sohn HS, Kim EN, Park JM, Chung YA (2001) Muscular sarcoidosis: Ga-67 scintigraphy and magnetic resonance imaging. Clin Nucl Med 26:29–32PubMedCrossRef
149.
150.
Zurück zum Zitat Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, Prystowsky S (2010) Neurosarcoidosis Presentations and Management. The Neurologiat 16:2–15CrossRef Terushkin V, Stern BJ, Judson MA, Hagiwara M, Pramanik B, Sanchez M, Prystowsky S (2010) Neurosarcoidosis Presentations and Management. The Neurologiat 16:2–15CrossRef
151.
Zurück zum Zitat Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE (2003) Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 48:3542–3354PubMedCrossRef Ulbricht KU, Stoll M, Bierwirth J, Witte T, Schmidt RE (2003) Successful tumor necrosis factor alpha blockade treatment in therapy-resistant sarcoidosis. Arthritis Rheum 48:3542–3354PubMedCrossRef
152.
Zurück zum Zitat Walter MC, Lochmuller H, Schlotter-Weigel B, Meindl T, Muller-Felber W (2003) Successful treatment of muscle sarcoidosis with thalidomide. Acta Myol 22:22–25PubMed Walter MC, Lochmuller H, Schlotter-Weigel B, Meindl T, Muller-Felber W (2003) Successful treatment of muscle sarcoidosis with thalidomide. Acta Myol 22:22–25PubMed
153.
Zurück zum Zitat Woitalla D, Henkes H, Felber S, Weber W, Janisch W, Kuhne D (2000) Clinical aspects and diagnostic imaging in sarcoidosis of the nervous system. Radiologe 40:1064–1076PubMedCrossRef Woitalla D, Henkes H, Felber S, Weber W, Janisch W, Kuhne D (2000) Clinical aspects and diagnostic imaging in sarcoidosis of the nervous system. Radiologe 40:1064–1076PubMedCrossRef
154.
Zurück zum Zitat Zettl UK, Lehmitz R, Mix E (2003) Klinische Liquordiagnostik. de Gruyter, Berlin, New York Zettl UK, Lehmitz R, Mix E (2003) Klinische Liquordiagnostik. de Gruyter, Berlin, New York
155.
Zurück zum Zitat ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus. Arthritis Rheum 42:599–608CrossRef ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature (1999) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus. Arthritis Rheum 42:599–608CrossRef
156.
Zurück zum Zitat Berlit P (2007) Neuropsychiatric disease in collagen vascular diseases and vasculitis. J Neurol 254:II87–89PubMedCrossRef Berlit P (2007) Neuropsychiatric disease in collagen vascular diseases and vasculitis. J Neurol 254:II87–89PubMedCrossRef
158.
Zurück zum Zitat Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834–4840PubMedPubMedCentralCrossRef Carson KR, Evens AM, Richey EA et al (2009) Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood 113:4834–4840PubMedPubMedCentralCrossRef
159.
Zurück zum Zitat Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162PubMedCrossRef Chan TM, Li FK, Tang CS et al (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 343:1156–1162PubMedCrossRef
160.
Zurück zum Zitat Hanly JG (2004) ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 13:861–864PubMedCrossRef Hanly JG (2004) ACR classification criteria for systemic lupus erythematosus: limitations and revisions to neuropsychiatric variables. Lupus 13:861–864PubMedCrossRef
161.
Zurück zum Zitat Harrison MJ, Ravdin LD, Lockshin MD (2006) Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 54:2515–2522PubMedCrossRef Harrison MJ, Ravdin LD, Lockshin MD (2006) Relationship between serum NR2a antibodies and cognitive dysfunction in systemic lupus erythematosus. Arthritis Rheum 54:2515–2522PubMedCrossRef
162.
Zurück zum Zitat Kimura A, Kanoh Y, Sakurai T et al (2010) Antibodies in patients with neuropsychiatric systemic lupus erythematosus. Neurology 74:1372–1379PubMedCrossRef Kimura A, Kanoh Y, Sakurai T et al (2010) Antibodies in patients with neuropsychiatric systemic lupus erythematosus. Neurology 74:1372–1379PubMedCrossRef
163.
Zurück zum Zitat Krämer M, Berlit P (2010) Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases. Rheumatol Int 30:1471–1476CrossRef Krämer M, Berlit P (2010) Systemic, secondary and infectious causes for cerebral vasculitis: clinical experience with 16 new European cases. Rheumatol Int 30:1471–1476CrossRef
164.
Zurück zum Zitat Maneiro JR, Lopez-Canoa N, Salgado E, Gomez-Reino JJ (2014) Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford) 53:834–838CrossRef Maneiro JR, Lopez-Canoa N, Salgado E, Gomez-Reino JJ (2014) Maintenance therapy of lupus nephritis with mycophenolate or azathioprine: systematic review and meta-analysis. Rheumatology (Oxford) 53:834–838CrossRef
165.
Zurück zum Zitat Moroni G et al (2014) Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford) 53:1570–1577CrossRef Moroni G et al (2014) Rituximab vs mycophenolate and vs cyclophosphamide pulses for induction therapy of active lupus nephritis: a clinical observational study. Rheumatology (Oxford) 53:1570–1577CrossRef
166.
Zurück zum Zitat Mosca M, Ruiz-Irastorza G, Khamashta MA, Hughes GR (2001) Treatment of systemic lupus erythematosus. Int Immunopharmacol 1:1065–1075PubMedCrossRef Mosca M, Ruiz-Irastorza G, Khamashta MA, Hughes GR (2001) Treatment of systemic lupus erythematosus. Int Immunopharmacol 1:1065–1075PubMedCrossRef
167.
Zurück zum Zitat Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731PubMedCrossRef Navarra SV, Guzman RM, Gallacher AE et al (2011) Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 377:721–731PubMedCrossRef
168.
Zurück zum Zitat Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR (2001) Systemic lupus erythematosus. Lancet 357:1027–1032PubMedCrossRef Ruiz-Irastorza G, Khamashta MA, Castellino G, Hughes GR (2001) Systemic lupus erythematosus. Lancet 357:1027–1032PubMedCrossRef
169.
Zurück zum Zitat Sibbitt WL Jr., Sibbitt RR, Brooks WM (1999) Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42:2026–2038PubMedCrossRef Sibbitt WL Jr., Sibbitt RR, Brooks WM (1999) Neuroimaging in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 42:2026–2038PubMedCrossRef
170.
Zurück zum Zitat Takada K, Illei GG, Boumpas DT (2001) Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10:154–161PubMedCrossRef Takada K, Illei GG, Boumpas DT (2001) Cyclophosphamide for the treatment of systemic lupus erythematosus. Lupus 10:154–161PubMedCrossRef
Metadaten
Titel
Autoimmunerkrankungen
verfasst von
Brigitte Storch-Hagenlocher, Dr.
Brigitte Wildemann, Prof. Dr.
Peter Berlit, Prof. Dr.
Markus Krämer, PD Dr.
Copyright-Jahr
2015
Verlag
Springer Berlin Heidelberg
DOI
https://doi.org/10.1007/978-3-662-46500-4_33

Update AINS

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.